Facio to discover FSHD clinical outcome measures based on real-world data


Leiden, the Netherlands - March 18, 2019

Facio Therapies announced today that it entered an agreement with the Centre for Human Drug Research (CHDR; Leiden, the Netherlands) on a study aimed at discovering FSHD clinical outcome measures based on real-world patient data obtained with the use of digital technologies. This exploratory study, which is co-financed by Facio and CHDR and will be… read more

Facio appoints Otto Postma Managing Director


Leiden, the Netherlands - February 28, 2019

Facio Therapies announced today that its Board appointed Otto Postma Managing Director of Facio Therapies B.V. and of its sister company, Facio Intellectual Property B.V. In these capacities, Otto succeeds David Dasberg, who passed away suddenly on  January 16, 2019. Otto Postma has been involved in Facio from the very beginning. While still working at… read more

Facio expands Scientific Advisory Board


Leiden, the Netherlands - February 11, 2019

Facio announced today that Prof. Dr. Gerd Schnorrenberg has agreed to join Facio’s Scientific Advisory Board. His strong drug discovery and development expertise will support Facio in its ongoing efforts to generate, select and optimize drug development candidates for specific use in treating FSHD. Gerd Schnorrenberg has extensive experience in pharmaceutical research and development in… read more

Facio’s Managing Director, David Dasberg, passes away suddenly


Leiden, the Netherlands - January 17, 2019

Facio Therapies announced today that David Dasberg, its Managing Director, passed away unexpectedly on January 16. David suffered a fatal heart attack during a walk in the Dolomite mountains in Northern Italy, where he was vacationing with friends. David had served as Managing Director since Facio’s inception in September 2014. He was 52 years old…. read more